251,914 Shares in Nkarta, Inc. (NASDAQ:NKTX) Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC acquired a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 251,914 shares of the company’s stock, valued at approximately $1,489,000.

Several other institutional investors have also modified their holdings of the stock. Marshall Wace LLP lifted its stake in Nkarta by 136.7% in the 2nd quarter. Marshall Wace LLP now owns 439,973 shares of the company’s stock valued at $2,600,000 after buying an additional 254,104 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Nkarta by 12.0% in the second quarter. Renaissance Technologies LLC now owns 912,872 shares of the company’s stock valued at $5,395,000 after buying an additional 98,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Nkarta by 36.9% in the second quarter. Dimensional Fund Advisors LP now owns 132,306 shares of the company’s stock worth $782,000 after buying an additional 35,643 shares in the last quarter. Federated Hermes Inc. boosted its position in Nkarta by 28,478.7% during the second quarter. Federated Hermes Inc. now owns 135,749 shares of the company’s stock worth $802,000 after acquiring an additional 135,274 shares during the last quarter. Finally, Meeder Asset Management Inc. purchased a new stake in Nkarta during the 2nd quarter valued at about $26,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HC Wainwright decreased their target price on shares of Nkarta from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 price target on shares of Nkarta in a report on Wednesday, August 14th. Finally, Raymond James raised Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 price objective on the stock in a research note on Wednesday, August 14th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $18.20.

Nkarta Stock Performance

NKTX stock opened at $4.21 on Wednesday. Nkarta, Inc. has a one year low of $1.28 and a one year high of $16.24. The firm has a market cap of $208.04 million, a PE ratio of -1.79 and a beta of 0.81. The firm’s 50 day moving average price is $5.47 and its 200-day moving average price is $6.67.

Nkarta (NASDAQ:NKTX) last posted its earnings results on Tuesday, August 13th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.15. Equities research analysts predict that Nkarta, Inc. will post -1.92 EPS for the current fiscal year.

Insider Buying and Selling at Nkarta

In other news, insider Alicia J. Hager sold 3,396 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $8.00, for a total value of $27,168.00. Following the sale, the insider now directly owns 103,819 shares of the company’s stock, valued at approximately $830,552. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.70% of the stock is currently owned by corporate insiders.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.